CN1410107A - 夏塔热片及其制备方法 - Google Patents
夏塔热片及其制备方法 Download PDFInfo
- Publication number
- CN1410107A CN1410107A CN 02140443 CN02140443A CN1410107A CN 1410107 A CN1410107 A CN 1410107A CN 02140443 CN02140443 CN 02140443 CN 02140443 A CN02140443 A CN 02140443A CN 1410107 A CN1410107 A CN 1410107A
- Authority
- CN
- China
- Prior art keywords
- parts
- xiatare
- tablet
- fructus terminaliae
- herba euphorbiae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 61
- 241001116389 Aloe Species 0.000 claims abstract description 25
- 235000011399 aloe vera Nutrition 0.000 claims abstract description 25
- 239000007788 liquid Substances 0.000 claims abstract description 23
- 239000000284 extract Substances 0.000 claims abstract description 12
- 238000001291 vacuum drying Methods 0.000 claims abstract description 11
- 238000002156 mixing Methods 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims description 47
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 241001534869 Terminalia Species 0.000 claims description 23
- 239000000843 powder Substances 0.000 claims description 21
- 229920002472 Starch Polymers 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 235000019698 starch Nutrition 0.000 claims description 11
- 239000008107 starch Substances 0.000 claims description 11
- 102000004190 Enzymes Human genes 0.000 claims description 10
- 108090000790 Enzymes Proteins 0.000 claims description 10
- 235000021355 Stearic acid Nutrition 0.000 claims description 10
- 238000007796 conventional method Methods 0.000 claims description 10
- 230000006837 decompression Effects 0.000 claims description 10
- 238000000605 extraction Methods 0.000 claims description 10
- 238000010438 heat treatment Methods 0.000 claims description 10
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 10
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 10
- 238000004064 recycling Methods 0.000 claims description 10
- 238000010992 reflux Methods 0.000 claims description 10
- 239000008117 stearic acid Substances 0.000 claims description 10
- 238000009495 sugar coating Methods 0.000 claims description 10
- 238000000643 oven drying Methods 0.000 claims description 9
- 208000017520 skin disease Diseases 0.000 claims description 8
- 238000005469 granulation Methods 0.000 claims description 7
- 230000003179 granulation Effects 0.000 claims description 7
- 239000012567 medical material Substances 0.000 claims description 7
- 239000000706 filtrate Substances 0.000 claims description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 5
- 229920000136 polysorbate Polymers 0.000 claims description 5
- 229920000053 polysorbate 80 Polymers 0.000 claims description 5
- 230000001185 psoriatic effect Effects 0.000 claims description 5
- 229940000033 dermatological agent Drugs 0.000 claims description 2
- 239000003241 dermatological agent Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 14
- 201000004681 Psoriasis Diseases 0.000 abstract description 10
- 241000221079 Euphorbia <genus> Species 0.000 abstract description 3
- 235000011517 Terminalia chebula Nutrition 0.000 abstract description 3
- 239000011248 coating agent Substances 0.000 abstract description 3
- 238000000576 coating method Methods 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 3
- 238000001914 filtration Methods 0.000 abstract description 2
- 238000010298 pulverizing process Methods 0.000 abstract 2
- 235000015489 Emblica officinalis Nutrition 0.000 abstract 1
- 244000277583 Terminalia catappa Species 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 60
- 239000002674 ointment Substances 0.000 description 48
- 241000699666 Mus <mouse, genus> Species 0.000 description 30
- 241001465754 Metazoa Species 0.000 description 20
- 239000000758 substrate Substances 0.000 description 19
- 239000009509 xiaoyin Substances 0.000 description 17
- 230000006870 function Effects 0.000 description 16
- 206010018691 Granuloma Diseases 0.000 description 15
- 235000009330 Terminalia Nutrition 0.000 description 15
- 230000037396 body weight Effects 0.000 description 15
- 210000002966 serum Anatomy 0.000 description 15
- 230000008961 swelling Effects 0.000 description 15
- 239000013642 negative control Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 210000000952 spleen Anatomy 0.000 description 13
- 230000009471 action Effects 0.000 description 12
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 11
- 241000700199 Cavia porcellus Species 0.000 description 9
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 230000001629 suppression Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 241000893974 Nannizzia fulva Species 0.000 description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 8
- 239000001301 oxygen Substances 0.000 description 8
- 230000000242 pagocytic effect Effects 0.000 description 8
- 229940099259 vaseline Drugs 0.000 description 8
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 7
- 208000003251 Pruritus Diseases 0.000 description 7
- 230000003064 anti-oxidating effect Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 230000003203 everyday effect Effects 0.000 description 7
- 210000001541 thymus gland Anatomy 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 206010048768 Dermatosis Diseases 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 6
- 229920000392 Zymosan Polymers 0.000 description 6
- 229920001525 carrageenan Polymers 0.000 description 6
- 235000010418 carrageenan Nutrition 0.000 description 6
- 238000002513 implantation Methods 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 229920000742 Cotton Polymers 0.000 description 5
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 5
- 108010006464 Hemolysin Proteins Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 241000223238 Trichophyton Species 0.000 description 5
- 229960004397 cyclophosphamide Drugs 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 210000002683 foot Anatomy 0.000 description 5
- 239000003228 hemolysin Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 244000101643 Aloe ferox Species 0.000 description 4
- 235000015858 Aloe ferox Nutrition 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 4
- 240000001624 Espostoa lanata Species 0.000 description 4
- 235000009161 Espostoa lanata Nutrition 0.000 description 4
- 241000233866 Fungi Species 0.000 description 4
- 241001494479 Pecora Species 0.000 description 4
- 206010070834 Sensitisation Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 229960003957 dexamethasone Drugs 0.000 description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 210000000440 neutrophil Anatomy 0.000 description 4
- 210000003024 peritoneal macrophage Anatomy 0.000 description 4
- 210000001539 phagocyte Anatomy 0.000 description 4
- 230000019254 respiratory burst Effects 0.000 description 4
- 230000008313 sensitization Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 244000144927 Aloe barbadensis Species 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 206010017533 Fungal infection Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000031888 Mycoses Diseases 0.000 description 3
- 241000238370 Sepia Species 0.000 description 3
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 3
- 238000011047 acute toxicity test Methods 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 210000005252 bulbus oculi Anatomy 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 229960002344 dexamethasone sodium phosphate Drugs 0.000 description 3
- PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 208000001848 dysentery Diseases 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229960001660 histamine phosphate Drugs 0.000 description 3
- ZHIBQGJKHVBLJJ-UHFFFAOYSA-N histamine phosphate Chemical compound OP(O)(O)=O.OP(O)(O)=O.NCCC1=CNC=N1 ZHIBQGJKHVBLJJ-UHFFFAOYSA-N 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000001788 irregular Effects 0.000 description 3
- 230000008557 oxygen metabolism Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 230000007306 turnover Effects 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 235000002961 Aloe barbadensis Nutrition 0.000 description 2
- 241001480043 Arthrodermataceae Species 0.000 description 2
- 241000407877 Combretum Species 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010015719 Exsanguination Diseases 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 241000001522 Terminalia chebula Species 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000001716 anti-fugal effect Effects 0.000 description 2
- 230000001139 anti-pruritic effect Effects 0.000 description 2
- 239000003908 antipruritic agent Substances 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000037304 dermatophytes Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000004345 fruit ripening Effects 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 210000004013 groin Anatomy 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000003448 neutrophilic effect Effects 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000004575 stone Substances 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- KJHJAABRDASKAF-UHFFFAOYSA-N 3,7-dihydropurine-2,6-dione Chemical compound OC1=NC(O)=C2N=CNC2=N1.O=C1NC(=O)NC2=C1NC=N2 KJHJAABRDASKAF-UHFFFAOYSA-N 0.000 description 1
- 240000006409 Acacia auriculiformis Species 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000974485 Aricia shasta Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010005913 Body tinea Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 241001147468 Chondrus ocellatus Species 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241001555026 Euphorbia humifusa Species 0.000 description 1
- 241001599881 Euphorbia maculata Species 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 208000010473 Hoarseness Diseases 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000222065 Lycoperdon Species 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 201000009053 Neurodermatitis Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241000768494 Polymorphum Species 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- 206010065954 Stubbornness Diseases 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 208000007712 Tinea Versicolor Diseases 0.000 description 1
- 206010067197 Tinea manuum Diseases 0.000 description 1
- 206010056131 Tinea versicolour Diseases 0.000 description 1
- 241000566916 Tomentella Species 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007159 enucleation Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 208000020694 gallbladder disease Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 108010084652 homeobox protein PITX1 Proteins 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 231100000668 minimum lethal dose Toxicity 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000002399 phagocytotic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035752 proliferative phase Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000002940 repellent Effects 0.000 description 1
- 239000005871 repellent Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 201000003875 tinea corporis Diseases 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 02140443 CN1226043C (zh) | 2002-07-11 | 2002-07-11 | 一种治疗银屑病的口服片剂的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 02140443 CN1226043C (zh) | 2002-07-11 | 2002-07-11 | 一种治疗银屑病的口服片剂的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1410107A true CN1410107A (zh) | 2003-04-16 |
CN1226043C CN1226043C (zh) | 2005-11-09 |
Family
ID=4750307
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 02140443 Expired - Lifetime CN1226043C (zh) | 2002-07-11 | 2002-07-11 | 一种治疗银屑病的口服片剂的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1226043C (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101391013B (zh) * | 2008-11-13 | 2010-12-01 | 陕西东泰制药有限公司 | 一种治疗皮肤病的中药制剂及其制备方法 |
CN102824518A (zh) * | 2012-09-21 | 2012-12-19 | 武汉市健恒药业有限公司 | 用于治疗皮肤真菌感染的中药 |
CN109700868A (zh) * | 2019-01-24 | 2019-05-03 | 依力扎提·阿布都哈克 | 一种用于治疗银屑病的中药冲剂及其制备方法 |
CN110801484A (zh) * | 2019-11-07 | 2020-02-18 | 朱德胜 | 一种治疗牛皮癣的药物及其制备方法 |
CN115607639A (zh) * | 2022-11-02 | 2023-01-17 | 陕西东泰制药有限公司 | 一种治疗银屑病的中药组合物及其制备方法 |
-
2002
- 2002-07-11 CN CN 02140443 patent/CN1226043C/zh not_active Expired - Lifetime
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101391013B (zh) * | 2008-11-13 | 2010-12-01 | 陕西东泰制药有限公司 | 一种治疗皮肤病的中药制剂及其制备方法 |
CN102824518A (zh) * | 2012-09-21 | 2012-12-19 | 武汉市健恒药业有限公司 | 用于治疗皮肤真菌感染的中药 |
CN102824518B (zh) * | 2012-09-21 | 2014-02-26 | 武汉市健恒药业有限公司 | 用于治疗皮肤真菌感染的中药 |
CN109700868A (zh) * | 2019-01-24 | 2019-05-03 | 依力扎提·阿布都哈克 | 一种用于治疗银屑病的中药冲剂及其制备方法 |
CN110801484A (zh) * | 2019-11-07 | 2020-02-18 | 朱德胜 | 一种治疗牛皮癣的药物及其制备方法 |
CN115607639A (zh) * | 2022-11-02 | 2023-01-17 | 陕西东泰制药有限公司 | 一种治疗银屑病的中药组合物及其制备方法 |
CN115607639B (zh) * | 2022-11-02 | 2023-11-28 | 陕西东泰制药有限公司 | 一种治疗银屑病的中药组合物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1226043C (zh) | 2005-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1740175A (zh) | 博落回总生物碱盐及其制备方法和应用 | |
CN1762967A (zh) | 甘草次酸衍生物、制备方法及其用途 | |
CN1810259A (zh) | 防治龋病的五倍子药物及其提取方法 | |
CN101028384A (zh) | 一种用于治疗妇科炎症的药物组合物及其制备方法和质量控制方法 | |
CN1917895A (zh) | 鱼腥草和插田泡的提取物及其用于预防和治疗过敏性疾病的组合物 | |
CN1226043C (zh) | 一种治疗银屑病的口服片剂的制备方法 | |
CN1672520A (zh) | 植物杀虫防病促长剂及其制备方法 | |
CN1663596A (zh) | 一种治疗慢性子宫颈炎的栓剂 | |
CN101036722A (zh) | 一种缓解疲劳、改善男性更年期综合征的保健食品及制备 | |
CN1883645A (zh) | 一组主要治疗痤疮的组合物 | |
CN1207032C (zh) | 一种治疗急慢性鼻渊的药物组合物及其制备方法 | |
CN1290529C (zh) | 治疗痛风、高尿酸血症和高脂血症的药物及其制备方法 | |
CN1197612C (zh) | 治疗泌尿系统结石和尿路感染疾病的中药制剂及其制备方法 | |
CN1056298C (zh) | 一种治疗软组织损伤的外用药及其生产方法 | |
CN1181871C (zh) | 地锦草软膏及其制备方法 | |
CN1335161A (zh) | 全鹿骨粉胶囊 | |
CN1237995C (zh) | 能够使异常黑胆质型体液成熟和清除的药物及其制备方法 | |
CN1660259A (zh) | 一种治疗肠易激综合征的中药及其制备方法 | |
CN1194743C (zh) | 一种治疗类风湿性关节炎的中药组合物及其制备方法和质量控制方法 | |
CN1927161A (zh) | 一种沐浴乳及其制备方法 | |
CN1323688C (zh) | 一种治疗前列腺疾病的药物组合物及其制备方法 | |
CN1679692A (zh) | 一种治疗淋病的药物及其制备方法 | |
CN1197611C (zh) | 治疗胆石症的药物及其制备方法 | |
CN1239199C (zh) | 一种治疗胃炎、消化性溃疡的药物及其制备方法 | |
CN1216614C (zh) | 一种延缓慢性肾功能衰竭的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: SLAV ABE Owner name: QIKANGHABO UYGUR MEDICINE CO., LTD., XINJIANG Free format text: FORMER OWNER: HAMLATI WFUER Effective date: 20110421 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 830001 NO. 36, YAN'AN ROAD, URUMQI CITY, XINJIANG UYGHUR AUTONOMOUS REGION TO: 830026 NO. 625, YINGBIN ROAD, URUMQI CITY, XINJIANG UYGHUR AUTONOMOUS REGION |
|
TR01 | Transfer of patent right |
Effective date of registration: 20110421 Address after: 830026 No. 625 Yingbin Road, the Xinjiang Uygur Autonomous Region, Urumqi Patentee after: QIKANGHABO UGGR MEDICINE Co.,Ltd. Address before: 830001 No. 36, Yanan Road, Urumqi, the Xinjiang Uygur Autonomous Region Co-patentee before: Slav Abbe Patentee before: Hamulati Wufuer Silafu Aibai |
|
C56 | Change in the name or address of the patentee |
Owner name: XINJIANG QIKANG HABO UIGUR MEDICINE CO., LTD. Free format text: FORMER NAME: QIKANGHABO UYGUR MEDICINE CO., LTD., XINJIANG |
|
CP01 | Change in the name or title of a patent holder |
Address after: 830026 No. 625 Yingbin Road, the Xinjiang Uygur Autonomous Region, Urumqi Patentee after: XINJIANG QIKANG HABO UIGHUR MEDICINE CO.,LTD. Address before: 830026 No. 625 Yingbin Road, the Xinjiang Uygur Autonomous Region, Urumqi Patentee before: QIKANGHABO UGGR MEDICINE Co.,Ltd. |
|
CP03 | Change of name, title or address |
Address after: 830000 the Xinjiang Uygur Autonomous Region Urumqi hi tech Industrial Development Zone (new urban area) 1375 Patentee after: New Qikang Pharmaceutical Co.,Ltd. Address before: 830026 Yingbin Road, Urumqi, the Xinjiang Uygur Autonomous Region 625 Patentee before: XINJIANG QIKANG HABO UIGHUR MEDICINE CO.,LTD. |
|
CP03 | Change of name, title or address | ||
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20051109 |